Market Overview

Alexion Says Clinical, Statistical Improvement in 2nd Endpoints of Eculizumab Study

Share:
Related ALXN
JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity
Wall Street Mixed On Biogen Before Earnings
Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On Debut (Seeking Alpha)

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented data from a single-arm, open-label, investigator-initiated Phase 2 study of eculizumab (Soliris^®) as an investigational therapy in 14 patients with severe, relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The study met its primary efficacy endpoint with high degrees of clinical and statistical significance. Clinically and statistically significant improvements were also observed in key secondary endpoints. Data were presented today at a Scientific Symposium Oral Session at the American Neurological Association annual meeting in Boston, Mass.^1

Posted-In: News FDA

 

Related Articles (ALXN)

Get Benzinga's Newsletters